Vertex Announces VX-445 Phase 3 Trial Program, Positive Data on VX-561 Combo Regimen
Vertex Pharmaceuticals is launching Phase 3 clinical trials to evaluate the safety and effectiveness of its investigational therapy,...
Galapagos to Start Trial Testing New Triple-Combo Therapy for CF
Galapagos is starting a clinical trial called FALCON to evaluate a new triple-combination therapy to treat cystic fibrosis patients. The...
Abnormal Glucose Levels Linked to Poorer Lung Function in Cystic Fibrosis Youth, Study Shows
Abnormalities in continuous glucose monitoring (CGM) measures correlate with a decline in lung function in children and adolescents with...
Vertex’s VX-659 Triple Combo To Be Tested in Phase 3 Trial in Patients with 2 Copies of F508del Muta
Vertex Pharmaceuticals is launching a new Phase 3 trial to assess the triple combination of VX-659 plus tezacaftor (VX-661) and Kalydeco...
Lung Bacteria in CF Children Is Present and Increases in Early Years of Life, Study Finds
Changes in bacteria present in the lower respiratory tract during the first years of life may be indicative of early progression of lung...
Lying Instead of Sitting During CF Inhalation Therapy Doesn’t Increase Delivery Time, Study Finds
It takes only slightly longer to deliver an inhaled therapy in cystic fibrosis (CF) patients sitting upright than when lying alternately...
Cystic Fibrosis-Related Diabetes
Cystic fibrosis-related diabetes (CFRD) is a unique type of diabetes that is common in people with CF. With early diagnosis and proper...
Mucociliary Clearence
Scott Donaldson, M.D., an associate professor of medicine and the director of the University of North Carolina adult CF center, provides...
